Oppenheimer analyst Jay Olson downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Outperform to Perform.The analyst comments: "MRK's acquisition of TERN for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades